| [1] |
Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma[J]. Thyroid, 1999, 9:421-427.
|
| [2] |
Koong S, Reynolds JC, Movius EG, et al. Lithium as a potential adjuvant to 131I theraphy of metastatic well-differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 1999, 84:912-916.
|
| [3] |
Arturi F, Russo D, Schlumberger M, et al. Iodide symporter gene expression in human thyroid tumors[J]. J Clin Endocrinol Metab, 1998, 83:2493-2496.
|
| [4] |
Shimura H, Haraguchi K, Miyazaki A, et al. Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symproter gene[J]. Endocrinology, 1997, 138:4493-4496.
|
| [5] |
Franke WG, Zophel K, Wunderlich GR, et al. Thyroperoxidase:a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study[J]. Cancer Detect Prey, 2000, 24(6):524-530.
|
| [6] |
Schmutzler C, Winzer R, Meissner WJ, et al. Retinoic acid increase sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells[J]. Biochem Biophys Res Commun, 1997, 240:832-838.
|
| [7] |
Simon D, Koehrle J, Reiners C, et al. Redifferentiation theraphy with retinoide:therapeutic option for advanced follicular and papillary thyroid carcinoma[J]. World J Surg, 1998, 22:569-574.
|
| [8] |
Grunwald F, Menzel C, Bender H, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer[J]. J Nucl Med, 1998, 39:1903-1906.
|